Masimo Co. (NASDAQ:MASI - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $194.88 and last traded at $190.63, with a volume of 896907 shares trading hands. The stock had previously closed at $188.77.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the stock. Stifel Nicolaus restated a "buy" rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. Raymond James raised their price objective on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. Wells Fargo & Company boosted their target price on Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, Piper Sandler raised their price target on Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $194.80.
Get Our Latest Stock Analysis on MASI
Masimo Stock Down 0.6 %
The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The stock has a market cap of $9.42 billion, a PE ratio of 120.36 and a beta of 1.02. The company has a 50 day moving average price of $174.88 and a two-hundred day moving average price of $155.41.
Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The business had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Analysts expect that Masimo Co. will post 4.1 EPS for the current year.
Institutional Investors Weigh In On Masimo
Hedge funds have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC raised its holdings in Masimo by 31.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 60 shares during the period. EverSource Wealth Advisors LLC raised its stake in Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 64 shares during the period. Blue Trust Inc. lifted its holdings in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 71 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Masimo by 0.8% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider's stock worth $1,622,000 after purchasing an additional 82 shares during the period. Finally, Thrivent Financial for Lutherans grew its holdings in Masimo by 0.8% during the 4th quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider's stock valued at $1,728,000 after buying an additional 83 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.
About Masimo
(
Get Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
See Also
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
